{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:29:53Z","timestamp":1793316593981,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:00:00Z","timestamp":1554249600000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jacc.2018.01.058","type":"journal-article","created":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T06:40:57Z","timestamp":1522651257000},"page":"1474-1482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":308,"title":["Angiotensin-Converting Enzyme Inhibitors in Hypertension"],"prefix":"10.1016","volume":"71","author":[{"given":"Franz H.","family":"Messerli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sripal","family":"Bangalore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Bavishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano F.","family":"Rimoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2018.01.058_bib1","unstructured":"Bacon Francis. Novum Organum Scientiarum. 1620."},{"key":"10.1016\/j.jacc.2018.01.058_bib2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1056\/NEJM197410172911611","article-title":"Editorial: Angiotensin inhibition","volume":"291","author":"Chobanian","year":"1974","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.01.058_bib3","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJM197805042981812","article-title":"Renin inhibitors","volume":"298","author":"Haber","year":"1978","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.01.058_bib4","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1001\/archinte.1996.00440160069010","article-title":"Angiotensin II receptor inhibition: a new therapeutic principle","volume":"156","author":"Messerli","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2018.01.058_bib5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1161\/CIRCULATIONAHA.108.828897","article-title":"Antihypertensive efficacy of aliskiren: is hydrochlorothiazide an appropriate benchmark?","volume":"119","author":"Messerli","year":"2009","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacc.2018.01.058_bib6","article-title":"Blood pressure lowering efficacy of renin inhibitors for primary hypertension","author":"Musini","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.jacc.2018.01.058_bib7","article-title":"Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension","author":"Heran","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.jacc.2018.01.058_bib8","article-title":"Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension","author":"Heran","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2018.01.058_bib9","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jacc.2010.07.053","article-title":"Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials","volume":"57","author":"Messerli","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.01.058_bib10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/jhh.2013.6","article-title":"Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril","volume":"27","author":"Bonner","year":"2013","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.jacc.2018.01.058_bib11","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/jch.12673","article-title":"Fixed-combination olmesartan\/amlodipine was superior to perindopril\u00a0+ amlodipine in reducing central systolic blood pressure in hypertensive patients with diabetes","volume":"18","author":"Ruilope","year":"2016","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jacc.2018.01.058_bib12","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1097\/HJH.0b013e32835466ac","article-title":"Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies","volume":"30","author":"Omboni","year":"2012","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.jacc.2018.01.058_bib13","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","article-title":"Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2018.01.058_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","article-title":"A\u00a0meta-analysis of the effects of treatment on left ventricular mass in essential hypertension","volume":"115","author":"Klingbeil","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2018.01.058_bib15","article-title":"Effects of ACEIs versus ARBs on proteinuria or albuminuria in primary hypertension: a meta-analysis of randomized trials","volume":"94","author":"Xu","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jacc.2018.01.058_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of\u00a0an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.01.058_bib17","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","article-title":"Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial","volume":"292","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.01.058_bib18","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.01.058_bib19","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/heartjnl-2016-310705","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk","volume":"103","author":"Potier","year":"2017","journal-title":"Heart"},{"issue":"8","key":"10.1016\/j.jacc.2018.01.058_bib20","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","author":"Li","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2018.01.058_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.mayocp.2015.10.019","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials","volume":"91","author":"Bangalore","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2018.01.058_bib22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijcard.2016.04.132","article-title":"ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure: a network meta-analysis","volume":"217","author":"Ricci","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2018.01.058_bib23","doi-asserted-by":"crossref","first-page":"d2234","DOI":"10.1136\/bmj.d2234","article-title":"Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials","volume":"342","author":"Bangalore","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2018.01.058_bib24","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.116.025950","article-title":"Angiotensin receptor blockers reduce cardiovascular events, including the risk of myocardial infarction","volume":"135","author":"Messerli","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.01.058_bib25","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.01.058_bib26","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.01.058_bib27","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.01.058_bib28","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529","article-title":"Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"10","author":"Burnett","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2018.01.058_bib29","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0140-6736(16)30969-2","article-title":"Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure","volume":"389","author":"Packer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.01.058_bib30","first-page":"543","article-title":"The transition from hypertension to heart failure: contemporary update","volume":"5","author":"Messerli","year":"2017","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2018.01.058_bib31","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.01.058_bib32","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2018.01.058_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189126","article-title":"Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: a nationwide study of therapy with renin-angiotensin system blockade","volume":"12","author":"Lin","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2018.01.058_bib34","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.01.058_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001971","article-title":"Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses","volume":"13","author":"Catala-Lopez","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.jacc.2018.01.058_bib36","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker j telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"Yusuf","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.01.058_bib37","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","article-title":"Telmisartan to prevent recurrent stroke and cardiovascular events","volume":"359","author":"Yusuf","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.01.058_bib38","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.amjcard.2016.07.074","article-title":"Meta-analysis of randomized trials on the efficacy and safety of angiotensin-converting enzyme inhibitors in patients\u00a0\u226565 years of age","volume":"118","author":"Bavishi","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2018.01.058_bib39","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.amjmed.2010.06.014","article-title":"Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians\u2019 Desk Reference","volume":"123","author":"Bangalore","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2018.01.058_bib40","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/bmj.38803.528113.55","article-title":"Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine","volume":"332","author":"McDowell","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2018.01.058_bib41","doi-asserted-by":"crossref","first-page":"183.e11","DOI":"10.1016\/j.amjmed.2009.06.032","article-title":"Angiotensin-converting enzyme-related cough among Chinese-Americans","volume":"123","author":"Tseng","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2018.01.058_bib42","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1016\/S0140-6736(17)32476-5","article-title":"Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional survey","volume":"390","author":"Su","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.01.058_bib43","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.amjcard.2012.03.034","article-title":"Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors","volume":"110","author":"Makani","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2018.01.058_bib44","doi-asserted-by":"crossref","first-page":"234","DOI":"10.7326\/0003-4819-117-3-234","article-title":"Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy:a review of the literature and pathophysiology","volume":"117","author":"Israili","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2018.01.058_bib45","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/jama.1997.03550030072037","article-title":"Recurrent angiotensin-converting enzyme inhibitor\u2013associated angioedema","volume":"278","author":"Brown","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.01.058_bib46","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0140-6736(00)02596-4","article-title":"Vasopeptidase inhibition and angio-oedema","volume":"356","author":"Messerli","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.01.058_bib47","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jaip.2017.02.018","article-title":"Epidemiology of ACE inhibitor angioedema utilizing a large electronic health record","volume":"5","author":"Banerji","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacc.2018.01.058_bib48","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/archinte.165.14.1637","article-title":"Incidence and characteristics of angioedema associated with enalapril","volume":"165","author":"Kostis","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2018.01.058_bib49","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0162-3109(99)00107-1","article-title":"Angioedema due to angiotensin-converting enzyme inhibitors","volume":"44","author":"Agostoni","year":"1999","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.jacc.2018.01.058_bib50","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.1988.03410070095035","article-title":"Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition","volume":"260","author":"Slater","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.01.058_bib51","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1001\/archinte.160.13.1905","article-title":"Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?","volume":"160","author":"Grossman","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2018.01.058_bib52","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1520\/JFS15129J","article-title":"Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease","volume":"46","author":"Dean","year":"2001","journal-title":"J\u00a0Forensic Sci"},{"key":"10.1016\/j.jacc.2018.01.058_bib53","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1097\/HJH.0000000000001052","article-title":"Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.jacc.2018.01.058_bib54","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.01.058_bib55","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1001\/archinte.160.11.1654","article-title":"Headache in mild-to-moderate hypertension and its reduction by irbesartan therapy","volume":"160","author":"Hansson","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2018.01.058_bib56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0140-6736(17)31468-X","article-title":"Are ACE inhibitors acceptable ingredients in polypills?","volume":"390","author":"Messerli","year":"2017","journal-title":"Lancet"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109718304315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109718304315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:15:42Z","timestamp":1760015742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109718304315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":56,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0735109718304315"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2018.01.058","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensin-Converting Enzyme Inhibitors in Hypertension","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2018.01.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}